TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10072958

Group type: EXPERIMENTAL
Intervention: Domestic bendazac lysine tablet
Number of subjects: 10

Group type: COMPARATOR
Intervention: Imported bendazac lysine tablet
Number of subjects: 10
Study: 8174201

Group type: EXPERIMENTAL
Intervention: recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 3344298

Group type: COMPARATOR
Intervention: Caffeine 0 mg (placebo)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Caffeine 125 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Caffeine 250 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Mental stress
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Caffeine (any dose)
Number of subjects: 36
Study: 30824960

Group type: EXPERIMENTAL
Intervention: Primary skin closure with a contralateral Penrose® drain
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional primary skin closure
Number of subjects: 70
Study: 28289240

Group type: EXPERIMENTAL
Intervention: Paracetamol (6 g daily for 3 days)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study: 26621127

Group type: EXPERIMENTAL
Intervention: Inflatable colon
Number of subjects: 273

Group type: COMPARATOR
Intervention: Standard display table method
Number of subjects: 273
Study: 23195389

Group type: EXPERIMENTAL
Intervention: Core‐Palliative Care Outcome Scale (Core‐POS)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: POS‐MS‐Symptoms (POS‐MS‐S)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Construct validity of Core‐POS and POS‐MS‐S
Number of subjects: 46
Study: 21328205

Group type: EXPERIMENTAL
Intervention: Multi-sensory environment therapy (24 sessions over 12 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Routine nursing home care (control group)
Number of subjects: 20
Study: 19690245

Group type: EXPERIMENTAL
Intervention: Intraoperative NG tube use
Number of subjects: 4055

Group type: EXPERIMENTAL
Intervention: Perioperative NG tube use
Number of subjects: 4055
Study: 16371613

Group type: EXPERIMENTAL
Intervention: 1 microg x kg(‐1) fentanyl and 0.02 mg x kg(‐1) midazolam intravenously
Number of subjects: 60

Group type: COMPARATOR
Intervention: iv saline (control)
Number of subjects: 60
Study: 12723100

Group type: EXPERIMENTAL
Intervention: New CrossAction manual toothbrush
Number of subjects: 15

Group type: COMPARATOR
Intervention: Worn CrossAction manual toothbrush
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: New Braun Oral‐B Battery (D4) toothbrush
Number of subjects: 15

Group type: COMPARATOR
Intervention: Worn Braun Oral‐B Battery (D4) toothbrush
Number of subjects: 15
Study: 10785215

Group type: EXPERIMENTAL
Intervention: Short protocol (group 3)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Long protocol starting on day 2 (group 1)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Long protocol starting on day 21 (group 2)
Number of subjects: 150
Study: 9484163

Group type: EXPERIMENTAL
Intervention: OptiBond adhesive liner
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional liners and bases
Number of subjects: 60
Study: 8396608

Group type: EXPERIMENTAL
Intervention: 0.1% all-trans retinoic acid cream
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 0.1% CD271 gel
Number of subjects: 25

Group type: COMPARATOR
Intervention: all-trans retinoic acid vehicle
Number of subjects: 25

Group type: COMPARATOR
Intervention: CD271 vehicle
Number of subjects: 25
Study: 3085363

Group type: EXPERIMENTAL
Intervention: 75 mg b.d. ranitidine
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 150 mg b.d. ranitidine
Number of subjects: 48

Group type: COMPARATOR
Intervention: 75 mg nocte ranitidine for prophylaxis
Number of subjects: 48

Group type: COMPARATOR
Intervention: 150 mg nocte ranitidine for prophylaxis
Number of subjects: 48
Study: 30683825

Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg three times daily)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Metformin (500 mg twice daily)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Low calorie diet (LC)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group (isocaloric diet)
Number of subjects: 114
Study: 27042999

Group type: EXPERIMENTAL
Intervention: VARIED (2-4 RM on Day 1, 8-12 RM on Day 2, 20-30 RM on Day 3 for 8 weeks)
Number of subjects: 19

Group type: COMPARATOR
Intervention: CONSTANT (8-12 RM per set for 8 weeks)
Number of subjects: 19
Study: 24991872

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEEs, 0.625 mg/day)
Number of subjects: 27347

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens and medroxyprogesterone acetate (MPA, 2.5 mg/day)
Number of subjects: 27347

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27347
Study: 23469188

Group type: EXPERIMENTAL
Intervention: Clinically integrated post‐graduate training programme in evidence-based medicine (5-day training including assignments, peer teaching, interactive training, lectures, brainstorming sessions)
Number of subjects: 132

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 132
Study: 20962743

Group type: EXPERIMENTAL
Intervention: Higher serum bicarbonate levels (20-30 mmol/l)
Number of subjects: 1094

Group type: EXPERIMENTAL
Intervention: Serum bicarbonate levels near 28-30 mmol/l
Number of subjects: 1094
Study: 18985810

Group type: EXPERIMENTAL
Intervention: Patient education
Number of subjects: 674
Study: 16611442

Group type: EXPERIMENTAL
Intervention: Formulation A (locally manufactured SP tablet formulation, 500 mg sulfadoxine and 25 mg pyrimethamine)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Formulation B (Fansidar, Hoffmann La Roche, Basel, Switzerland, 500 mg sulfadoxine and 25 mg pyrimethamine)
Number of subjects: 12
Study: 14514234

Group type: EXPERIMENTAL
Intervention: PLGA (10 recessions)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: SDDA (10 recessions)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: CTG (10 recessions)
Number of subjects: 22
Study: 10646612

Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: SCID II
Number of subjects: 17
Study: 8665770

Group type: EXPERIMENTAL
Intervention: Lower body negative pressure at -15 mmHg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Lower body negative pressure at -40 mmHg
Number of subjects: 14
Study: 1679076

Group type: EXPERIMENTAL
Intervention: Perineal cleansing
Number of subjects: 192

Group type: COMPARATOR
Intervention: Non-cleansing
Number of subjects: 192
Study: 6800389

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg orally)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Acebutolol (200 mg orally)
Number of subjects: 7
Study: 31242340

Group type: EXPERIMENTAL
Intervention: Pleasant imagery and relaxation instruction (PIRI) video
Number of subjects: 154

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Prevention of post‐rape stress (PPRS) video
Number of subjects: 154
Study: 28476486

Group type: EXPERIMENTAL
Intervention: Endometrial scratch (ES)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Endocervical manipulation (control)
Number of subjects: 299
Study: 25963311

Group type: EXPERIMENTAL
Intervention: Not guaranteed benefit statement
Number of subjects: 584

Group type: COMPARATOR
Intervention: Some but very small chance benefit statement
Number of subjects: 584
Study: 23707275

Group type: EXPERIMENTAL
Intervention: Social observational learning condition (OLC)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Verbal suggestion condition (VSC)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control condition (CC)
Number of subjects: 85
Study: 21802589

Group type: EXPERIMENTAL
Intervention: Training (T) - 2 full days of hands-on course over a 3-month period
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control (S) - No training
Number of subjects: 31
Study: 19302250

Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg daily for 7 days
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 17904459

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 612

Group type: COMPARATOR
Intervention: Control (sotalol and placebo combined)
Number of subjects: 612
Study: 15779583

Group type: EXPERIMENTAL
Intervention: Standardised questionnaire on knowledge and attitudes towards tuberculosis
Number of subjects: 205
Study: 12500362

Group type: EXPERIMENTAL
Intervention: New informational materials developed by the Centers for Medicare & Medicaid Services (CMS) as part of the National Medicare Education Program (NMEP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 9291444

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (16 patients) or guided drug therapy (electrophysiologically guided class I antiarrhythmic drugs = 7 patients; Holter‐guided class III antiarrhythmic drugs = 16 patients)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Holter‐guided class III antiarrhythmic drugs
Number of subjects: 111

Group type: COMPARATOR
Intervention: Beta blockers
Number of subjects: 111

Group type: COMPARATOR
Intervention: No antiarrhythmic drug therapy
Number of subjects: 111
Study: 7949090

Group type: EXPERIMENTAL
Intervention: Bleeding time test
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Intravenous aspirin (500 mg)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (0.3 mg)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Preoperative bleeding time parameters
Number of subjects: 118
Study: 3599793

Group type: EXPERIMENTAL
Intervention: One capsule t.d.s. of terpene mixture (Rowachol)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Two capsules t.d.s. of terpene mixture (Rowachol)
Number of subjects: 36

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 36
Study: 29140959

Group type: EXPERIMENTAL
Intervention: Continuous proximal adductor canal block (ACB)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Continuous distal adductor canal block (ACB)
Number of subjects: 73
Study: 28774331

Group type: EXPERIMENTAL
Intervention: Staging radioactive particle implantation guided by CT and fiber bronchoscopy
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 102
Study: 25630641

Group type: COMPARATOR
Intervention: Rifampicin (10 mg/kg body weight)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Rifampicin plus 150 mg of SQ109
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Rifampicin plus 300 mg of SQ109
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: SQ109 alone
Number of subjects: 90
Study: 24014482

Group type: EXPERIMENTAL
Intervention: Health mentor (HM) group received regular calls from trained community health nurses.
Number of subjects: 182

Group type: COMPARATOR
Intervention: Usual care (UC) group received GP care plus non-interventional brief phone calls.
Number of subjects: 182
Study: 21372751

Group type: EXPERIMENTAL
Intervention: DTaP‐IPV‐Hep B‐PRP‐T vaccine (Hexaxim)
Number of subjects: 624

Group type: COMPARATOR
Intervention: Pentaxim and Engerix B Pediatrico (Hep B monovalent) vaccines
Number of subjects: 624
Study: 18201291

Group type: EXPERIMENTAL
Intervention: Coated graft
Number of subjects: 40

Group type: COMPARATOR
Intervention: Uncoated graft
Number of subjects: 40
Study: 15946871

Group type: EXPERIMENTAL
Intervention: Levetiracetam (1500 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 12816172

Group type: EXPERIMENTAL
Intervention: Disease management program
Number of subjects: 406

Group type: COMPARATOR
Intervention: Usual practice
Number of subjects: 406
Study: 11347331

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (200 mg, i.v., every other day, 10 doses, total course dose 2 g)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Methylprednisolone and cyclophosphamide (200 mg, i.v., on methylprednisolone-free days, 10 doses plus 200 mg i.v. once a month for 3 months, total course dose 2.6 g)
Number of subjects: 70
Study: 8636283

Group type: EXPERIMENTAL
Intervention: GnRH agonist (goserelin, 3.6‐mg implant) for 9 months
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: GnRH agonist (goserelin) + estrogen‐progestin replacement therapy (HRT)
Number of subjects: 39

Group type: COMPARATOR
Intervention: GnRH agonist (goserelin)
Number of subjects: 39
Study: 1334713

Group type: EXPERIMENTAL
Intervention: Alprazolam (1.5 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 2-Deoxyglucose (2DG, 50 mg/kg)
Number of subjects: 10
Study: 6428577

Group type: EXPERIMENTAL
Intervention: Elemental diet (Vivonex) for four weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Prednisolone 0.75 mg/kg/day for four weeks
Number of subjects: 21
Study: 31655016

Group type: EXPERIMENTAL
Intervention: Erythropoiesis stimulating agents (ESAs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood withdrawal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exercise-induced muscle damage
Number of subjects: 0
Study: 28443388

Group type: EXPERIMENTAL
Intervention: Ultrasound guidance with real-time transthoracic echocardiography and chest ultrasonography
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional group (CXR)
Number of subjects: 60
Study: 28198972

Group type: EXPERIMENTAL
Intervention: Modified step‐back technique
Number of subjects: 90

Group type: COMPARATOR
Intervention: Rotational technique
Number of subjects: 90

Group type: COMPARATOR
Intervention: Reciprocal technique
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All techniques
Number of subjects: 90
Study: 25148814

Group type: COMPARATOR
Intervention: Routine specialty care (RSC)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Daily remote glucose monitoring (RGM)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 28
Study: 24135012

Group type: EXPERIMENTAL
Intervention: Fosphenytoin (20 phenytoin equivalents/kg)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study: 21487653

Group type: EXPERIMENTAL
Intervention: quetiapine (400 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: matched placebo
Number of subjects: 20
Study: 18764912

Group type: EXPERIMENTAL
Intervention: HFA-ethanol MDI
Number of subjects: 31

Group type: COMPARATOR
Intervention: Baseline BEC
Number of subjects: 31
Study: 17154092

Group type: EXPERIMENTAL
Intervention: Methylprednisolone iv pulse therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glucocorticoids (small doses and short periods)
Number of subjects: 0

Group type: COMPARATOR
Intervention: High dose of pulse therapy (9-12g)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cumulative dose limited to 4.5-6g
Number of subjects: 0
Study: 14550588

Group type: EXPERIMENTAL
Intervention: Acetic-acid visualization (VIA)
Number of subjects: 12992

Group type: EXPERIMENTAL
Intervention: Magnified acetic-acid visualization (VIAM)
Number of subjects: 12992

Group type: EXPERIMENTAL
Intervention: Spatula+cotton swab‐Papanicolaou (Pap) smear (SS)
Number of subjects: 12992

Group type: EXPERIMENTAL
Intervention: Cervical brush‐Pap smear (CB)
Number of subjects: 12992
Study: 11069196

Group type: EXPERIMENTAL
Intervention: 30 mg risedronate daily for 2 weeks
Number of subjects: 0
Study: 8619935

Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen treatment in ER positive subgroup
Number of subjects: 98

Group type: COMPARATOR
Intervention: Adjuvant tamoxifen treatment in ER negative subgroup
Number of subjects: 98
Study: 1345799

Group type: EXPERIMENTAL
Intervention: Ganciclovir
Number of subjects: 234

Group type: COMPARATOR
Intervention: Foscarnet
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 234
Study: 6421395

Group type: EXPERIMENTAL
Intervention: Regular physical exercise for two months
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (29 men)
Number of subjects: 31
Study: 29722250

Group type: EXPERIMENTAL
Intervention: Muscular Hypertrophy (MH) training
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Muscular Endurance (ME) training
Number of subjects: 23
Study: 29609254

Group type: EXPERIMENTAL
Intervention: Comprehensive intervention group
Number of subjects: 799

Group type: EXPERIMENTAL
Intervention: Health literacy intervention group
Number of subjects: 799

Group type: EXPERIMENTAL
Intervention: Exercise intervention group
Number of subjects: 799

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 799
Study: 26888587

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) treatment for 4 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (rehabilitation treatment as usual)
Number of subjects: 36
Study: 24628923

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (doses between 75 and 260 U, average 163 U per treatment cycle, administered every 12 weeks)
Number of subjects: 2436

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2436
Study: 22333336

Group type: EXPERIMENTAL
Intervention: Brief alcohol intervention
Number of subjects: 152

Group type: COMPARATOR
Intervention: Attention-placebo control
Number of subjects: 152
Study: 19734008

Group type: EXPERIMENTAL
Intervention: Modified Tampa Scale for Kinesiophobia (11 items out of 16)
Number of subjects: 347

Group type: COMPARATOR
Intervention: Original Tampa Scale for Kinesiophobia (17 items)
Number of subjects: 347
Study: 18034980

Group type: EXPERIMENTAL
Intervention: Olopatadine hydrochloride nasal spray, 665 mcg (OLO)
Number of subjects: 425

Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 425

Group type: COMPARATOR
Intervention: Mometasone furoate monohydrate, 50 mcg (MM)
Number of subjects: 425
Study: 16273964

Group type: EXPERIMENTAL
Intervention: High job strain
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Highest strain-ratio category
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Highest job-strain ratio category with low previous computer use
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low job strain
Number of subjects: 0
Study: 11900102

Group type: EXPERIMENTAL
Intervention: Change-detection paradigm using objects defined by color with location or shape
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Focused attention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Integrated format of visual memory
Number of subjects: 0
Study: 9927369

Group type: EXPERIMENTAL
Intervention: Inhaled lidocaine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 7558529

Group type: EXPERIMENTAL
Intervention: 3‐5 sets of 10 maximal concentric actions on an accommodating resistance device
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 3‐5 sets of 8‐12 coupled eccentric/concentric actions on a weight training device
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Isokinetic dynamometer training
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CT scans measuring cross-sectional area
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Biceps type I and II fiber area measurements
Number of subjects: 12
Study: 2075140

Group type: EXPERIMENTAL
Intervention: Alugastrin (30 mL liquid form)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gastrin (tablet form)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Wikalina (tablet form)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alusal (other brand)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Magnosil (other brand)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Maalox (control)
Number of subjects: 0
Study: 7459426

Group type: EXPERIMENTAL
Intervention: Buffered tablet formulation of oxyphenbutazone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Commercially available product of oxyphenbutazone
Number of subjects: 0
Study: 31225984

Group type: EXPERIMENTAL
Intervention: Synthetic clinical trial data extraction modules
Number of subjects: 281

Group type: COMPARATOR
Intervention: Synthetic clinical trial
Number of subjects: 281
Study: 28614691

Group type: EXPERIMENTAL
Intervention: Intravenous amphotericin B deoxycholate (0.7 to 1.0 mg/kg/day)
Number of subjects: 440

Group type: COMPARATOR
Intervention: Itraconazole capsules (600 mg/day for 3 days, then 400 mg/day for 11 days)
Number of subjects: 440
Study: 25679199

Group type: EXPERIMENTAL
Intervention: e-learning supported Train-the-Trainer programme
Number of subjects: 45

Group type: COMPARATOR
Intervention: Traditional guideline dissemination
Number of subjects: 45
Study: 23124692

Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT) procedure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT) procedure with concomitant cystocele repair
Number of subjects: 0
Study: 21074150

Group type: EXPERIMENTAL
Intervention: Levonorgestrel intrauterine system (LNG‐IUS)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Hysterectomy
Number of subjects: 75
Study: 19601705

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg once daily for 4 weeks
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Antacid use
Number of subjects: 356
Study: 16183201

Group type: EXPERIMENTAL
Intervention: Doppler sonography in Parkinsonian patients
Number of subjects: 47

Group type: COMPARATOR
Intervention: Doppler sonography in age and sex matched controls
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Doppler parameters in patients within each Hoehn‐Yahr scale
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Correlation of patient age and disease duration with Doppler parameters
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Values of vertebral, internal carotid and cerebral blood flow volumes (CBF), peak systolic velocities, and cross‐sectional areas
Number of subjects: 47
Study: 11954943

Group type: EXPERIMENTAL
Intervention: Nicorandil (100 microg/kg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 32
Study: 10369154

Group type: EXPERIMENTAL
Intervention: Depressed patients
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 20

Group type: COMPARATOR
Intervention: Recovered patients
Number of subjects: 20
Study: 7730925

Group type: EXPERIMENTAL
Intervention: Academic group detailing by pharmacists, 4 sessions
Number of subjects: 134

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 134
Study: 2183543

Group type: EXPERIMENTAL
Intervention: beclamide
Number of subjects: 23

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 23
Study: 6104743

Group type: EXPERIMENTAL
Intervention: Prenalterol (beta 1‐adrenoceptor agonist)
Number of subjects: 0